These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38593195)

  • 1. Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Zürcher SJ; Signorell A; Léchot-Huser A; Aebi C; Huber CA
    Vaccine; 2023 Nov; 41(48):7226-7233. PubMed ID: 38593195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coverage rates and timeliness of nationally recommended vaccinations in Swiss preschool children: A descriptive analysis using claims data.
    Schneider R; Reinau D; Schur N; Blozik E; Früh M; Signorell A; Heininger U; Schwenkglenks M; Meier CR
    Vaccine; 2020 Feb; 38(6):1551-1558. PubMed ID: 31791812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timeliness and completeness of routine childhood vaccinations in young children residing in a district with recurrent vaccine-preventable disease outbreaks, Jerusalem, Israel.
    Stein-Zamir C; Israeli A
    Euro Surveill; 2019 Feb; 24(6):. PubMed ID: 30755293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-appropriate versus up-to-date coverage of routine childhood vaccinations among young children in Israel.
    Stein-Zamir C; Israeli A
    Hum Vaccin Immunother; 2017 Sep; 13(9):2102-2110. PubMed ID: 28696824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands.
    Tielemans SMAJ; de Melker HE; Hahné SJM; Boef AGC; van der Klis FRM; Sanders EAM; van der Sande MAB; Knol MJ
    BMJ; 2017 Aug; 358():j3862. PubMed ID: 28855159
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 2014.
    Hill HA; Elam-Evans LD; Yankey D; Singleton JA; Kolasa M
    MMWR Morb Mortal Wkly Rep; 2015 Aug; 64(33):889-96. PubMed ID: 26313470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How are children who are delayed in the Childhood Vaccination Programme vaccinated: A nationwide register-based cohort study of Danish children aged 15-24 months and semi-structured interviews with vaccination providers.
    Pedersen KB; Holck ME; Jensen AKG; Suppli CH; Benn CS; Krause TG; Sørup S
    Scand J Public Health; 2020 Feb; 48(1):96-105. PubMed ID: 30024308
    [No Abstract]   [Full Text] [Related]  

  • 9. National, state, and selected local area vaccination coverage among children aged 19-35 months - United States, 2013.
    Elam-Evans LD; Yankey D; Singleton JA; Kolasa M;
    MMWR Morb Mortal Wkly Rep; 2014 Aug; 63(34):741-8. PubMed ID: 25166924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines.
    Dolhain J; Janssens W; Dindore V; Mihalyi A
    Expert Rev Vaccines; 2020 May; 19(5):419-443. PubMed ID: 32419537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timeliness of routine immunization in non-preterm children less than 2 years old using electronic data capture in an ambulatory setting in France in the context of vaccine hesitancy.
    Rybak A; Vié le Sage F; Béchet S; Werner A; Thiebault G; Bakhache P; Virey B; Caulin E; Cohen R; Levy C
    Arch Pediatr; 2019 Feb; 26(2):56-64. PubMed ID: 30638762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timeliness of routine immunization in a population-based Italian cohort of very preterm infants: results of the ACTION follow-up project.
    Tozzi AE; Piga S; Corchia C; Di Lallo D; Carnielli V; Chiandotto V; Fertz MC; Miniaci S; Rusconi F; Cuttini M
    Vaccine; 2014 Feb; 32(7):793-9. PubMed ID: 24397902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months.
    Zepp F; Behre U; Kindler K; Laakmann KH; Pankow-Culot H; Mannhardt-Laakmann W; Beckers F; Descamps D; Willems P
    Eur J Pediatr; 2007 Aug; 166(8):857-64. PubMed ID: 17541639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Sep; 62(36):733-40. PubMed ID: 24025754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
    Paulke-Korinek M; Fischmeister G; Grac A; Rendi-Wagner P; Kundi M; Mohsenzadeh-Rabbani A; Moritz K; Fenninger B; Jarisch R; Jasinska J; Holzmann H; Wiedermann U; Kollaritsch H
    Vaccine; 2011 Jul; 29(32):5130-6. PubMed ID: 21624412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine.
    Bayliss J; Nissen M; Prakash D; Richmond P; Oh KB; Nolan T
    Hum Vaccin Immunother; 2021 Jan; 17(1):176-190. PubMed ID: 32573398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination Coverage Among Children Aged 19-35 Months - United States, 2015.
    Hill HA; Elam-Evans LD; Yankey D; Singleton JA; Dietz V
    MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(39):1065-1071. PubMed ID: 27711036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'.
    Rieckmann A; Hærskjold A; Benn CS; Aaby P; Lange T; Sørup S
    Int J Epidemiol; 2019 Dec; 48(6):2026-2038. PubMed ID: 31062020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.